FARMINGDALE, N.Y., June 20, 2019 (GLOBE NEWSWIRE) — Misonix, Inc. (Nasdaq: MSON) (“Misonix”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it has received a letter from the Division of Enforcement of the Securities and Exchange Commission (the “SEC”) on June 18, 2019, stating that the SEC has concluded …